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Abstract This study is aimed at assessing by intra-
vascular ultrasound virtual histology (VH-IVUS) the
effect of statins on coronary bifurcation atherosclerosis
in non-culprit vessels. In this non-randomized study, in
48 patients, 51 bifurcation atherosclerotic sites in non-
culprit vessels without significant angiographic steno-
sis, underwent baseline and 12 months follow-up VH-
IVUS. Patients received treatment with either simva-
statin (20 mg daily, n = 24) or rosuvastatin (10 mg
daily, n = 24) for the same period. VH-IVUS analysis
of bifurcation lesions included the 5-mm proximal,
bifurcation only (side-branch point) and 5-mm distal
subsegments. Overall plaque and external elastic
membrane volume decreased after 1 year (115.7 ±
35.5 to 106.1 ± 29.3 mm3, P \ 0.001; and 241.0 ±
57.0 to 232.4 ± 54.2 mm3, P = 0.005, respectively).
Similarly, overall dense calcium volume significantly
increased (7.1 ± 5.3 to 11.0 ± 8.5 mm3, P \ 0.010),
while fibrous and fibrofatty volumes significantly
decreased (36.9 ± 19.2 to 24.1 ± 11.7 mm3, P \
0.001; and 5.1 ± 3.8 to 2.3 ± 2.0 mm3, P \ 0.001,
respectively), and necrotic core volume did not
change significantly (17.0 ± 11.1 to 19.8 ± 13.5 mm3,
P = 0.053). There were no significant differences in
compositional analysis between the simvastatin and
rosuvastatin treatment groups. However, within
groups, necrotic core volume significantly increased
in the simvastatin treatment group (19.7 ± 13.9 to
24.3 ± 16.1 mm3, P = 0.029) but not in the rosuvast-
atin treatment group. (14.3 ± 6.7 to 15.6 ± 8.7 mm3,
P = 0.423). The independent clinical predictors for
reduction of necrotic core volume by multiple stepwise
logistic regression analysis were the percent change of
HDL-cholesterol level (P = 0.041, odds ratio: 1.052,
95% confidence interval (CI): 1.002 to 1.104) and the
percent change of hsCRP level (P = 0.021, odds ratio:
0.989, 95% CI: 0.980 to 0.998). After 1 year, overall
dense calcium volume significantly increased whilst
fibrous and fibrofatty volumes significantly decreased;
no significant change in the content of necrotic core
was observed. Although changes in the volumes of all
plaque components were not significantly different
between the simvastatin and rosuvastatin treatment
groups, halting of necrotic core progression was
apparent in the rosuvastatin group.
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Introduction
Bifurcation sites are prone to develop atherosclerosis,
as well as necrotic core-rich plaques [1–3]. As
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compared to other lesion subsets, percutaneous coro-
nary intervention for bifurcation lesions is associated
with a lower rate of procedural success and a higher
rate of restenosis compared with that of non-bifurca-
tion lesions [4–6]. Whether underlying plaque com-
position plays a role in this difference remains
unknown.
Statin therapy improves long-term clinical out-
comes in patients with coronary artery disease, and an
intravascular ultrasound (IVUS) study has demon-
strated the benefits of statin therapy on regression of
coronary plaque size [7–9]. However, the effect of
statin treatment on plaque composition in bifurcation
lesions yet has not been evaluated. Intravascular
ultrasound virtual histology (VH-IVUS), which per-
mits the analysis of coronary plaque composition in
vivo with high predictive accuracy, is increasingly
used in clinical research [10–13]. Therefore, the aim of
this study is to assess the effects of 1 year of treatment
with statins on coronary bifurcation atherosclerosis of
non-culprit vessels by VH-IVUS.
Methods
Study population
This study was conducted in one Korean center and
included 48 consecutive patients with VH-IVUS
assessment who had undergone successful elective
coronary artery stenting with intermediate atheroscle-
rosis in a non-culprit vessel. Enrollment period
spanned from June 2005 to May 2006. These patients
were randomly treated with simvastatin (20 mg daily)
or rosuvastatin (10 mg daily) for a period of 1 year.
Forty-eight patients with 51 de novo non-culprit
bifurcation atherosclerotic sites without significant
stenosis by coronary angiogram (diameter stenosis
\50%) were included in the study. Only one site,
namely the most proximal bifurcation site ([1.5 mm
side-branch ostium diameter) was selected from one
major coronary vessel. All patients underwent base-
line and 12-month VH-IVUS imaging. The exclusion
criteria were hemodynamically unstable patients,
cardiogenic shock, left main bifurcation and previous
history of administration of lipid-lowering agents
including statins. During the 1-year follow-up, the
occurrence of major adverse cardiac events including
death of any causes, acute myocardial infarction
(elevation of the creatine kinase-myocardial band
fraction to a value 3 times the upper limit of normal),
and target-lesion revascularization (percutaneous or
surgical intervention of these nonstenotic bifurcation
lesions) was recorded. This study was performed with
the patient’s written informed consent and approval of
the institutional review board.
VH-IVUS examination and analysis
Baseline and 1-year follow-up VH-IVUS examinations
were performed before any intervention and after
intracoronary administration of 200 lg nitroglycerin
with a motorized transducer pullback system (0.5 mm/s).
The 2.9-F IVUS imaging catheter (Eagle Eye, Volcano
Corp., Rancho Cordova, California) incorporated a
20-MHz phased-array transducer. Off line analyses
were done with personal computer VH program
software (Volcano Therapeutics, Rancho Cordova,
California) by an examiner who was unaware of the
clinical characteristics of the subjects. We analyzed
geometric and compositional characteristics of the
5 mm-proximal, bifurcation only and 5 mm-distal
subsegments at the bifurcation sites (Fig. 1) Geometric
quantitative IVUS analyses were performed according
to criteria of the clinical expert consensus document on
IVUS. External elastic membrane (EEM), lumen, and
plaque & media (P&M) (P&M = EEM—lumen) areas
were obtained [14]. Plaque burden was defined as
P&M divided by EEM area 9100.
Compositional tissue characteristics were
expressed in colors, as previously described (green
for fibrous, yellow-green for fibrofatty, white for dense
calcium, and red for necrotic core area) [15]. The VH-
IVUS analyses were reported in volumes and as
percentages of volume. Percent change (%) of all
variables was calculated as follows: ([follow-up
value - baseline value]/[baseline value] 9 100).
Statistical analysis
All analyses were done using SPSS (version 16.0;
SPSS Inc, Chicago, Illinois). Data are presented as
frequencies or mean ± 1SD. Comparison was per-
formed with Chi-square statistics or Fisher exact test
and paired or unpaired Student t test or Mann–
Whitney U test accordingly. Nonparametric analysis
with Wilcoxon signed rank test was also done. All
patients were categorized as NC progressors (i.e.,
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patients with an increase in necrotic core volume after
1 year) and NC regressors (i.e., patients who had a
decrease in necrotic core volume). Logistic regression
analysis was performed to assess independent clinical
predictors of decrease in necrotic core volume at
1 year. Statistical significance was accepted as P less
than 0.05.
Results
Table 1 shows the baseline and clinical characteristics
of the patients. Mean age of study participants was
61.3 ± 8.5 years, and there were 29 male subjects
(60%). The studied bifurcation site was the left
anterior descending artery and diagonal branch in 27
patients (56.3%), the left circumflex artery and obtuse
marginal branch in 8 (16.6%) and the right coronary
artery and acute marginal branch in 13 (27.1%).
Table 1 shows not significant differences at baseline
clinical characteristics between simvastatin and rosu-
vastatin treatment groups.
There were no significant differences at baseline
and 12 months follow-up in high density lipoprotein
(HDL)-, low density lipoprotein (LDL)-cholesterol
and high sensitivity C-reactive protein (hsCRP) levels
between the simvastatin and rosuvastatin treatment
groups (Table 2). However, compared with the sim-
vastatin treatment group, percent change of hsCRP
level was significantly larger in the rosuvastatin
treatment group (11.1 ± 116.1 vs. –53.5 ± 41.3 mg/
l, P = 0.016). No major adverse cardiac events
occurred during the 12-month follow-up period.
Serial changes of geometric and compositional
variables in all patients
Geometric and compositional analyses are shown in
Table 3. Overall, there were significant changes in
geometric IVUS plaque volumes: EEM volume
Fig. 1 Schematic definition of proximal, bifurcation only and
distal subsegments for bifurcation sites. The proximal and distal
subsegments of the bifurcation site were analyzed in the 5-mm
proximal and distal to the bifurcation sites. The bifurcation-only
segments were analyzed in each subsegment length. After
1 year, all subsegments show increased dense calcium by
Virtual Histology intravascular ultrasound (a proximal; b bifur-
cation only; and c distal subsegments)
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(241.0 ± 57.0 to 232.4 ± 54.2 mm3, P = 0.005),
P&M volume (115.7 ± 35.5 to 106.1 ± 29.3 mm3,
P \ 0.001). The VH-IVUS analysis showed that dense
calcium volume significantly increased (7.1 ± 5.3 to
11.0 ± 8.5 mm3, P \ 0.001), while fibrous and fib-
rofatty plaque volumes significantly decreased
(36.9 ± 19.2 to 24.1 ± 11.7 mm3, P \ 0.001; and
5.1 ± 3.8 to 2.3 ± 2.0 mm3, P \ 0.001, respectively)
after statin treatment for a period of 1 year. Although
necrotic core percentage increased after 1 year, the
volume change did not achieve statistical significance
(17.0 ± 11.1 to 19.8 ± 13.5 mm3, P = 0.053).
Differential effect of statins on geometric
and compositional variables
In both statin groups, there were significant changes
in plaque volumes from baseline to follow-up
(125.3 ± 44.0 to 113.5 ± 33.5 mm3, P = 0.018 in
the simvastatin treatment group; and 106.5 ± 22.0 to
98.9 ± 23.0 mm3, P = 0.001 in the rosuvastatin
treatment group) (Table 4). In both groups, there
was a significant increase in dense calcium volume
(7.8 ± 5.8 to 13.6 ± 10.5 mm3, P \ 0.001 in the
simvastatin treatment group; and 6.4 ± 4.9 to
8.5 ± 4.8 mm3, P = 0.008 in the rosuvastatin treat-
ment group), while fibrous and fibrofatty volumes
significantly decreased (41.1 ± 23.6 to 23.8 ±
12.2 mm3, P \ 0.001, and 5.7 ± 4.3 to 2.1 ±
2.2 mm3, P = 0.001, respectively, in the simvastatin
treatment group; and 33.0 ± 13.0 to 24.2 ±
11.4 mm3, P \ 0.001, and 4.6 ± 3.3 to 2.4 ±
1.8 mm3, P = 0.001, respectively, in the rosuvastatin
treatment group). While necrotic core volume
increased in the simvastatin treatment group (19.7 ±
13.9 mm3 to 24.3 ± 16.1 mm3, P = 0.029) and in
Table 1 Baseline clinical
characteristics between
simvastatin and rosuvastatin
treatment groups
Values are presented as number
(%) or mean ± SD
ACS acute coronary syndrome,
PCI percutaneous coronary
intervention, CABG coronary
artery bypass grafting, CAD
coronary artery disease, ACE
angiotensin converting
enzyme, LAD left anterior
descending artery, LCX left
circumflex artery, OM obtuse
marginal artery, AM acute
marginal artery
Simvastatin (n = 24) Rosuvastatin (n = 24) P
Age (years) 60.2 ± 8.2 61.6 ± 9.3 0.45
Male 16 (72.7) 13 (56.5) 0.21
Body mass index (kg/m2) 25.4 ± 2.6 25.2 ± 3.77 0.82
History
Previous ACS 0 0
Previous PCI 0 0
Previous CABG (%) 1 (4.2) 0 0.24
Risk factors
Hypertension 13 (56.5) 16 (64.0) 0.41
Hypercholesterolemia 7 (30.4) 10 (40.0) 0.35
Diabetes mellitus 6 (26.1) 7 (28.0) 0.57
Current smoking 7 (30.4) 7 (28.0) 0.55
Family history of CAD 1 (4.3) 1 (4.0) 0.73
Medication (%)
Aspirin 24 (100) 24 (100)
ACE inhibitor 4 (17) 7 (29) 0.50
Beta blocker 19 (79) 22 (92) 0.50
Calcium antagonist 20 (83) 19 (79) 0.74
Clopidogrel 23 (96) 24 (100) 0.49
Clinical presentation 0.27
Stable angina 9 (38) 13 (54) 0.40
ACS 14 (58) 12 (50) 0.40
Bifurcation site
LAD and diagonal 11 (47.8) 16 (64.0) 0.46
LCX and OM 4 (17.4) 4 (16.0) 0.46
RCA and AM 8 (34.8) 5 (20.0) 0.22
Follow-up period (day) 359 ± 37 361 ± 19 0.80
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patients treated with rosuvastatin, necrotic core progres-
sion was halted (14.3 ± 6.7 to 15.6 ± 8.7 mm3,
P = 0.423). Also, there were no significant differences
of changes in volume for each of the plaque components
between the simvastatin and rosuvastatin treatment
groups (P values are not shown) (Table 4). Of note, most
patients in the rosuvastatin treatment group (n = 18,
75%) had mean hsCRP levels below the mean of the
population and 50% had mean levels of both LDL-
cholesterol and hsCRP levels below the mean of the
population at 1 year. However, in the simvastatin
treatment group, 13 patients (55%) had mean hsCRP
levels and 38% had mean levels of both LDL-cholesterol
and hsCRP below the mean of the population at 1 year.
Overall, twenty-seven patients had mean value of
LDL-cholesterol levels below the mean of the
Table 2 Laboratory results
Values are presented
mean ± SD
HDL-C high-density
lipoprotein cholesterol,
LDL-C low-density
lipoprotein cholesterol,
hsCRP high sensitivity
C-reactive protein
*P = 0.48; P = 0.013
Baseline Follow-up Percent change (%) P
Body mass index 25.5 ± 3.5 25.3 ± 3.2 -0.6 ± 6.0 0.406
Total cholesterol (mg/dl) 181.0 ± 46.4 133.5 ± 26.3 -23.2 ± 19.3 \0.001
Triglyceride (mg/dl) 187.9 ± 154.5 121.4 ± 66.4 -21.3 ± 36.3 0.004
HDL-Cholesterol (mg/dl) 47.1 ± 18.0 52.2 ± 12.9 16.2 ± 24.9 0.032
Simvastatin 45.6 ± 11.7 51.5 ± 13.2 14.5 ± 19.5 0.004
Rosuvastatin 48.5 ± 22.8 53.0 ± 12.8 17.9 ± 29.7 0.051
LDL-cholesterol (mg/dl) 100.0 ± 41.5 57.0 ± 21.2 -37.1 ± 29.4 \0.001
Simvastatin 105.5 ± 50.2 60.6 ± 20.9 -33.9 ± 29.9* \0.001
Rosuvastatin 94.4 ± 30.6 53.4 ± 21.4 -40.2 ± 29.2* \0.001
hsCRP (mg/l) 3.9 ± 6.9 1.0 ± 0.8 -20.5 ± 92.9 \0.001
Simvastatin (mean) 2.1 ± 2.7 1.1 ± 0.7 11.1 ± 116.1 0.096
Simvastatin (median) 1.2 (0.6–2.0) 0.5 (0.5–1.8)
Rosuvastatin (mean) 5.7 ± 9.2 0.9 ± 0.9 -53.5 ± 41.3 \0.001
Rosuvastatin (median) 2.4 (1.4–5.0) 0.7 (0.4–1.2)
Table 3 Changes in
geometric and
compositional
characteristics at bifurcation
sites
Values are presented
mean ± SD
EEM external elastic
membrane, P&M plaque
and media, DC dense
calcium, FI fibrous, FF
fibrofatty, NC necrotic core
Baseline
(n = 51)
Follow-up
(n = 51)
Percent change
(%)
P
Analyzed segments (mm)
Total bifurcation length 13.5 ± 1.2 13.5 ± 1.1
Distal segment length 5.0 ± 0.1 5.0 ± 0.1
Just bifurcation length 2.5 ± 0.7 2.5 ± 0.7
Proximal segment length 5.0 ± 0.3 5.0 ± 0.3
EEM volume (mm3) 241.0 ± 57.0 232.4 ± 54.2 -3.2 ± 7.3 0.005
Lumen volume (mm3) 125.2 ± 31.7 126.3 ± 31.3 1.3 ± 8.7 0.476
P&M volume mm3 115.7 ± 35.5 106.1 ± 29.3 -7.0 ± 11.3 \0.001
Plaque burden (%) 47.7 ± 7.0 45.5 ± 5.7 -4.1 ± 7.7 \0.001
Absolute volume (mm3)
DC 7.1 ± 5.3 11.0 ± 8.5 92.5 ± 143.4 \0.001
FI 36.9 ± 19.2 24.1 ± 11.7 -28.3 ± 28.8 \0.001
FF 5.1 ± 3.8 2.3 ± 2.0 -32.5 ± 60.7 \0.001
NC 17.0 ± 11.1 19.8 ± 13.5 29.4 ± 61.7 0.053
Percentages (%)
DC (%) 11.0 ± 6.9 18.8 ± 10.7 115.1 ± 155.5 \0.001
FI (%) 55.8 ± 10.6 44.2 ± 15.8 -19.8 ± 27.9 \0.001
FF (%) 8.0 ± 4.8 4.4 ± 3.4 -21.9 ± 75.8 \0.001
NC (%) 25.2 ± 9.0 32.6 ± 10.6 45.8 ± 68.8 \0.001
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population, and among them, 9 patients had a decrease
in necrotic core volume 1 year later (3 patients were
treated with simvastatin and 6 patients were treated with
rosuvastatin). In addition, 31 patients had mean hsCRP
levels below the mean of the population and among
them, 8 patients had a decrease in necrotic core volume.
All of them were rosuvastatin-treated patients (Fig. 2).
Serial changes in geometric and compositional
variables in bifurcation subsegments
Subsegmental analyses in bifurcation lesions are
shown in Table 5. EEM, Plaque area and plaque
burden decreased after 1 year in all bifurcation
subsegments. At baseline and follow-up, dense cal-
cium and necrotic core areas including percentages of
proximal subsegments were significantly greater than
those of distal bifurcation subsegments. Of interest, in
all bifurcation subsegments, dense calcium area increased
after 1 year (0.66 ± 0.53 vs. 1.00 ± 0.77 mm2 in prox-
imal; 0.51 ± 0.44 vs. 0.81 ± 0.71 mm2 in bifurcation
only; and 0.39 ± 0.39 vs. 0.63 ± 0.65 mm2 in distal
subsegments). Fibrous and fibrofatty areas decreased
after 1 year in all subsegments. Necrotic core area
remained unchanged but relative content (percentage)
increased in all 3 subsegments (Table 5).
Independent clinical predictors for decrease
in necrotic core volume
All baseline, demographic and laboratory measure-
ments were tested in univariate analysis for their
correlation with a decrease in necrotic core volume.
All variables that had a P \ 0.2 value were entered
Table 4 Comparison of
changes in geometric and
compositional
characteristics at bifurcation
sites between the
simvastatin and rosuvastatin
treatment groups
Values are presented
mean ± SD
EEM external elastic
membrane, P&M plaque
and media, DC dense
calcium, FI fibrous, FF
fibrofatty, NC necrotic core
*P \ 0.396; P \ 0.355;
§P \ 0.567; }P \ 0.122
Baseline Follow-up Percent change (%) P
Simvastatin 20 mg (n = 24)
EEM (mm3) 255.6 ± 67.6 243.2 ± 62.1 -4.2 ± 8.5 0.026
Lumen (mm3) 130.2 ± 38.5 129.7 ± 37.7 0.05 ± 9.4 0.827
P&M (mm3) 125.3 ± 44.0 113.5 ± 33.5 -6.7 ± 13.4 0.018
Absolute volume (mm3)
DC (mm3) 7.8 ± 5.8 13.6 ± 10.5 110.1 ± 151.1 \0.001
FI (mm3) 41.1 ± 23.6 23.8 ± 12.2 -32.2 ± 29.2 \0.001
FF (mm3) 5.7 ± 4.3 2.1 ± 2.2 -37.5 ± 58.7 0.001
NC (mm3) 19.7 ± 13.9 24.3 ± 16.1 43.1 ± 70.5 0.029
Percentages (%)
DC (%) 10.6 ± 5.8 20.0 ± 10.3 127.8 ± 148.5* \0.001
FI (%) 55.5 ± 10.9 40.6 ± 15.9 -26.3 ± 26.6 \0.001
FF (%) 8.1 ± 5.2 3.9 ± 3.3 -29.3 ± 70.3§ 0.001
NC (%) 25.7 ± 9.7 35.5 ± 10.3 59.3 ± 79.4} 0.001
Rosuvastatin 10 mg (n = 24)
Vessel (mm3) 226.9 ± 40.9 222.0 ± 44.1 -2.3 ± 5.8 0.087
Lumen (mm3) 120.4 ± 23.1 123.1 ± 23.8 2.4 ± 8.0 0.168
Plaque (mm3) 106.5 ± 22.0 98.9 ± 23.0 -7.2 ± 9.2 0.001
Absolute volume (mm3)
DC (mm3) 6.4 ± 4.9 8.5 ± 4.8 75.6 ± 136.4 0.008
FI (mm3) 33.0 ± 13.0 24.2 ± 11.4 -24.6 ± 28.4 \0.001
FF (mm3) 4.6 ± 3.3 2.4 ± 1.8 -27.6 ± 63.3 0.001
NC (mm3) 14.3 ± 6.7 15.6 ± 8.7 16.3 ± 49.9 0.423
Percentages (%)
DC (%) 11.4 ± 7.9 17.7 ± 11.1 102.9 ± 163.9* \0.001
FI (%) 56.2 ± 10.6 47.6 ± 15.2 -13.7 ± 28.3 0.006
FF (%) 7.8 ± 4.4 4.8 ± 3.5 -14.7 ± 81.6§ 0.006
NC (%) 24.6 ± 8.5 29.8 ± 10.4 32.9 ± 55.2} 0.036
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into the multiple logistic regression model; variables
included gender, age, types of statin, clinical status,
percent change of plaque volume, percent change of
HDL-cholesterol level and percent change of hsCRP
level. Ultimately, the two independent clinical pre-
dictors for decrease in necrotic core volume were the
percent change of HDL-cholesterol level (P = 0.041,
odds ratio: 1.052, 95% confidence interval (CI): 1.002
to 1.104) and percent change of hsCRP level
(P = 0.021, odds ratio: 0.989, 95% CI: 0.980 to
0.998).
Discussion
The present study shows for the first time serial
changes in geometric and compositional characteris-
tics of coronary atherosclerotic plaques at bifurcation
sites by intravascular ultrasound virtual histology in
patients treated with statins. The main findings of this
study are: (1) Overall plaque volume at bifurcations
significantly decreased following 1 year of statin
treatment. (2) Overall mean dense calcium and
necrotic core areas of proximal subsegments were
larger than those of distal bifurcation subsegments. (3)
At 1 year, overall and in each bifurcation subsegment,
dense calcium volume significantly increased, while
fibrous and fibrofatty volumes significantly decreased,
and necrotic core volume did not change significantly.
(4) At 1 year, there were no significant differences in
plaque component volumes between the simvastatin
and rosuvastatin treatment groups. However, within
groups, necrotic core volume significantly increased in
the simvastatin treatment group, while there was no
increase in necrotic core volume in the rosuvastatin
treatment group. (5) The independent predictors by
multiple stepwise logistic regression analysis of
decrease in necrotic core volume were the percent
change of HDL-cholesterol level and the percent
change of hsCRP level.
Many clinical trials have shown that statins can
significantly reduce the incidence of cardiovascular
events in both primary and secondary prevention [16,
17]. Although imaging studies of coronary plaques have
contributed considerably to our understanding of the
benefits of lipid-lowering therapies, effect of statin
treatment on bifurcation coronary plaques using VH-
IVUS has not been sufficiently evaluated. In addition,
the effect of statins on plaque size cannot be seen as a
class effect, because the results of various studies have
shown different effect. For example, in the REVERSAL
[9] study, moderate lipid-lowering therapy with 40 mg
of pravastatin did not halt plaque progression, while
treatment with 80 mg of atorvastatin did. The first study
showing reduction on plaque size was the ASTEROID
trial using 40 mg of rosuvastatin [8]. However, these
trials have only evaluated quantitative changes of
coronary artery plaque using gray-scale IVUS but did
not study plaque composition change. Although several
recent papers showed various results on serial changes
of plaque composition with various statin treatments,
none of them focused on bifurcation lesions.
In a previous study, patients with stable angina
pectoris (n = 80) treated with fluvastatin for 1 year had
significant regression of plaque volume, and changes in
atherosclerotic plaque composition with a significant
reduction of fibrofatty volume (P \ 0.0001). This
change in fibrofatty volume had a significant correlation
with change in LDL-cholesterol level (r = 0.703,
P \ 0.0001) and change in hsCRP level (r = 0.357,
P = 0.006) [18]. Of note, the necrotic core did not
change significantly. In a randomized study by Hong
et al., that included 100 patients with stable angina and
ACS treated with rosuvastatin 10 mg and simvastatin
20 mg for 1 year, overall necrotic core volume signif-
icantly decreased (P = 0.010) and fibrofatty plaque
volume increased (P = 0.006) after statin treatments.
Particularly, there was a significant decrease in necrotic
Fig. 2 End of study LDL-cholesterol and hsCRP values.
Dotted lines indicate the mean values for the population in this
study. Fifty percent of the rosuvastatin treatment group is below
the mean LDL cholesterol and hsCRP levels at follow-up (white
circle = simvastatin treatment group, black circle = rosuvast-
atin treatment group)
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Table 5 Changes of geometric
and compositional
characteristics for each
bifurcation subsegment
Values are presented
mean ± SD
EEM external elastic
membrane, P&M plaque and
media, DC dense calcium, FI
fibrous, FF fibrofatty, NC
necrotic core
Baseline (n = 51) Follow-up (n = 51) Percent change (%) P
Geometric parameters
Proximal
EEM (mm2) 19.0 ± 4.1 18.3 ± 4.0 -3.8 ± 4.6 \0.001
Lumen (mm2) 9.4 ± 2.6 9.5 ± 2.5 2.4 ± 11.2 0.924
P&M (mm2) 9.6 ± 2.7 8.7 ± 2.2 -7.9 ± 10.0 \0.001
Plaque burden (%) 50.4 ± 8.7 47.9 ± 6.8 -4.2 ± 8.7 \0.001
Bifurcation only
EEM (mm2) 18.1 ± 4.0 17.4 ± 3.9 -3.7 ± 6.6 \0.001
Lumen (mm2) 9.8 ± 2.5 9.7 ± 2.4 -0.3 ± 9.3 0.862
P&M (mm2) 8.3 ± 2.9 7.7 ± 2.3 -5.3 ± 14.5 0.002
Plaque burden (%) 45.2 ± 9.8 43.9 ± 8.1 -1.9 ± 11.5 0.042
Distal
EEM (mm2) 16.5 ± 3.9 16.0 ± 3.9 -2.9 ± 5.5 \0.001
Lumen (mm2) 8.8 ± 2.2 8.8 ± 2.2 0.8 ± 8.0 0.847
P&M (mm2) 7.7 ± 2.8 7.1 ± 2.5 -6.0 ± 11.8 0.001
Plaque burden (%) 45.9 ± 8.8 44.0 ± 8.1 -3.4 ± 8.9 0.004
Compositional parameters
Proximal
DC (mm2) 0.66 ± 0.53 1.00 ± 0.77 137.1 ± 270.4 \0.001
DC (%) 11.6 ± 8.1 19.2 ± 11.9 174.4 ± 353.9 \0.001
FI (mm2) 3.14 ± 1.60 2.04 ± 1.03 -24.0 ± 43.1 \0.001
FI (%) 55.0 ± 12.6 43.5 ± 17.0 -19.0 ± 32.3 \0.001
FF (mm2) 0.39 ± 0.29 0.19 ± 0.19 -22.8 ± 74.7 \0.001
FF (%) 7.2 ± 4.8 4.1 ± 3.5 -12.9 ± 95.9 \0.001
NC (mm2) 1.55 ± 0.90 1.74 ± 1.07 30.1 ± 65.7 0.072
NC (%) 26.2 ± 9.7 33.2 ± 11.2 45.8 ± 82.2 0.001
Bifurcation only
DC (mm2) 0.51 ± 0.44 0.81 ± 0.71 145.0 ± 247.0 \0.001
DC (%) 10.9 ± 8.6 19.0 ± 12.3 223.1 ± 381.5 \0.001
FI (mm2) 2.67 ± 1.51 1.81 ± 1.04 -26.0 ± 34.3 \0.001
FI (%) 56.3 ± 12.6 45.9 ± 17.7 -18.5 ± 27.7 \0.001
FF (mm2) 0.42 ± 0.32 0.19 ± 0.18 -27.2 ± 75.1 \0.001
FF (%) 9.4 ± 6.3 5.1 ± 3.9 -12.9 ± 100.6 \0.001
NC (mm2) 1.21 ± 1.00 1.39 ± 1.08 42.6 ± 93.0 0.208
NC (%) 23.4 ± 10.8 29.9 ± 11.8 56.5 ± 96.3 0.001
Distal
DC (mm2) 0.39 ± 0.39 0.63 ± 0.65 133.3 ± 363.8 \0.001
DC (%) 9.7 ± 7.4 16.9 ± 11.0 152.3 ± 301.3 \0.001
FI (mm2) 2.36 ± 1.44 1.61 ± 1.06 -26.4 ± 32.6 \0.001
FI (%) 58.7 ± 11.4 47.4 ± 17.2 -18.0 ± 29.5 \0.001
FF (mm2) 0.35 ± 0.30 0.15 ± 0.14 -36.7 ± 57.3 \0.001
FF (%) 9.1 ± 5.6 5.0 ± 4.8 -24.3 ± 79.9 \0.001
NC (mm2) 1.00 ± 0.94 1.24 ± 1.07 46.8 ± 95.4 0.021
NC (%) 22.5 ± 10.3 30.7 ± 12.4 61.3 ± 97.1 \0.001
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core volume (P = 0.015) in the rosuvastatin-treated
subgroup. However, in our study only including bifur-
cation lesions, necrotic core content did not decrease
and dense calcium content significantly increased in
rosuvastatin-treated patients. It is not clear whether
these are lesion-specific findings. Also at variance with
our study, by multiple stepwise logistic regression
analysis, they showed that the only independent clinical
predictor of decrease in necrotic core volume was
baseline HDL-cholesterol level (P = 0.040, odds ratio:
1.044, 95% confidence interval (CI): 1.002 to 1.089)
[19]. In our study, we found that the independent clinical
predictors by multiple stepwise logistic regression
analysis of decrease in necrotic core volume were the
percent change (i.e. instead of baseline value as in the
study by Hong et al.) of HDL-cholesterol level
(P = 0.041, odds ratio: 1.052, 95% confidence interval
(CI): 1.002 to 1.104) and percent change of hsCRP level
(P = 0.021, odds ratio: 0.989, 95% CI: 0.980 to 0.998).
It has been suggested that the efficacy of statin
therapy is partly due to the ‘‘anti-inflammatory’’
properties of these agents, that is they have also a
marked LDL cholesterol-independent effect [20]. In
the JUPITER trial, 17802 subjects with no history of
cardiovascular disease, low LDL cholesterol level
(\130 mg/dl), and a high plasma level of C-reactive
protein (CRP C 2 mg/dl), were randomized to rosu-
vastatin 20 mg or placebo daily. There was a 46%
reduction in cardiovascular events for patients ran-
domized to rosuvastatin (P \ 0.0001). Thus, the
JUPITER trial substantiates that the benefits of statins
relate in part to decreased inflammation. In our study,
there was a significant change in hsCRP level only in
the rosuvastatin treatment group. Indeed patients who
achieved hsCRP values below the mean of the
population and presented a decrease in NC were
treated with rosuvastatin. Due to the nature of the
present study (i.e. retrospective), in the group of
patients receiving rosuvastatin, the baseline hsCRP
values were somehow higher as compared to those in
the simvastatin group.
It has been reported in another manuscript which
plaque burden and necrotic core are larger in bifurca-
tion lesions compared to non-bifurcation lesions [21].
Thus, it is expected that a greater change would occur
in bifurcation lesions. To our knowledge this is the first
report looking specifically into changes within bifur-
cation lesions.
Limitations
This study has several limitations. (1) It is a retro-
spective and single-center study. (2) It includes a
relatively small population to show serial changes in
plaque composition. To avoid type II error, a prospec-
tive, double blinded, large study is needed to compare
the changes in plaque composition between statin
treatment groups. The ongoing IBIS 3 study, not only
evaluates the serial compositional changes in a long
coronary segment ([40 mm) in patients receiving
40 mg rosuvastatin but it will also specifically assesses
serial compositional changes in bifurcation lesions.
The current report did not include the assessment of
bifurcation angle (BA), we rather looked into the serial
changes in plaque size and composition within bifurca-
tion lesions. It is known that the BA can influence the
presence and phenotype of atherosclerotic plaque in the
proximal bifurcation segment. Data from computational
fluid dynamics and histopathology studies have con-
firmed this finding by demonstrating that the hemody-
namic phenomena, which are important in atherogenesis,
are more pronounced in the large angle bifurcation.
Conclusions
After 1 year, overall dense calcium volume signifi-
cantly increased whilst fibrous and fibrofatty volumes
significantly decreased and no significant change in
the content of necrotic core was observed in bifurca-
tion lesion. The changes in the volumes of all plaque
components were not statistically different between
the simvastatin and rosuvastatin treatment groups;
however, halting of necrotic core progression was
apparent in the rosuvastatin group.
Conflict of interest None.
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